At a glance

ClinicalIndex Comparison Record

N/AUnknown· 100 enrolled

Drug / intervention

Eltrombopag +1 moredrug

Likely dose

Eltrombopag 50mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04214951

NCT04214951N/AUnknown

Compare CT.gov

A Prospective Observational Study of Switching Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

Peking University People's Hospital·observational·Posted Jan 2, 2020·Updated Oct 20, 2020

In Brief

An observational study evaluating Eltrombopag and Recombinant human thrombopoietin (rh-TPO) for Corticosteroid-resistant or Relapsed ITP. Targeting 100 participants across 1 site.

Detailed Summary

Thrombopoietin Receptor Agonists (TPO-ra) are novel treatments for patients with refractory Primary Immune Thrombocytopenia (ITP). Rh-TPO and eltrombopag increase the number of platelets through different mechanism. If there is cross-resistance between 2 drugs for the treatment of adult ITP is still no answer. The purpose of this study is to investigate the efficacy and safety of switching eltrombopag and Rh-TPO in adults with ITP.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsCorticosteroid-resistant or Relapsed ITP

CountriesChina

Collaborators--

Timeline

N/AUnknownOverdue

2020202120222023202420252026

Enrollment StartJan 2020

First PostedJan 2020

Primary CompletionAug 2022

Study CompletionDec 2022

TodayJul 2026

First PostedJan 2, 2020

Enrollment StartJan 1, 2020

Primary CompletionAug 1, 2022

Study CompletionDec 1, 2022

TodayJul 2, 2026

Enrollment to primary: 2.6 yearsPosted 6.5 years ago

Interventions

Eltrombopagdrug

Patients will be given eltrombopag 50mg once daily for 6 weeks.

Recombinant human thrombopoietin (rh-TPO)drug

Patients will be given rh-TPO 300 U/kg once daily for 21 days.